Individualized Sunitinib Dosing Improves Response, Survival in RCC

Individualizing first-line sunitinib was associated with improved response and survival times among patients with metastatic renal cell carcinoma.

Source: CancerNetwork - June 5, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Renal Cell Carcinoma News Source Type: news